Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Comment by bligickaon Jan 26, 2021 11:43am
56 Views
Post# 32387605

RE:RE:RE:RE:Made-in-Canada coronavirus vaccine starts human clinical tri

RE:RE:RE:RE:Made-in-Canada coronavirus vaccine starts human clinical tri

Pending regulatory approval, the company's CEO Brad Sorenson says a larger Phase 2 trial may follow in May with seniors, younger subjects and pregnant people.

Providence uses messenger R-N-A technology for a product it calls P-T-X COVID-19 B.

Sorenson says if successful, the vaccine could be released by the end of the year.




bligicka wrote: Nice how they got Goverment Funding !!! ....too bad Goren only cares about PP's and cheap warrants for the insiders ....Why can't Vaxil get Goverment Funding ???








bligicka wrote:

Purchased Calgary site

The federal government provided financial sponsorship and support for the early phase clinical trial through the National Research Council of Canada's Industrial Research Assistance Program. 

Currently, Canada lacks the capacity to manufacture the millions of doses of coronavirus vaccines needed to immunize people outside of a clinical trial setting. It's why the federal government struck deals with Pfizer and Moderna — both manufactured abroad — to obtain the vaccines being rolled out across Canada.

While the company was developing the vaccine in pre-clinical studies, Sorenson said it also started to build the infrastructure to manufacture the vaccine in Canada as well.
-------------------------------------------------------------------------------------
Nice how they got Goverment Funding !!! ....too bad Goren only cares about PP's and cheap warrants for the insiders ....Why can't Vaxil get Goverment Funding ???





<< Previous
Bullboard Posts
Next >>